Novartis' Tabrecta Nets Full FDA Approval for NSCLC With METex14 Skipping Mutations
The drug received accelerated approval two years earlier, but now the FDA is granting full approval based on confirmatory evidence of activity.
European Commission Approves Novartis MET Inhibitor Tabrecta for Advanced NSCLC
The agent is approved for non-small cell lung cancer patients in Europe whose tumors harbor METex14 skipping and who received prior immunotherapy and/or chemo.
EMA's CHMP Recommends Novartis' Tabrecta for Previously Treated NSCLC With METex14 Skipping Mutation
The European Commission will review the committee's recommendation and decide whether to approve the MET inhibitor for this indication in Europe.
Lung Cancer Research Foundation, MET Crusaders to Fund MET-Driven Cancer Research Projects
This year, LCRF and the patient advocacy group MET Crusaders plan to support two specific research projects into cancers driven by MET alterations.
FDA Approves Foundation Medicine's Liquid Biopsy Test as CDx for Novartis' Tabrecta in NSCLC
The blood-based test is the second Foundation Medicine assay approved to ID patients eligible for the drug due to mutations leading to MET exon 14 skipping.